Zhang Xiuming, Liu Jimin, Yan Sheng, Huang Ke, Bai Yanfeng, Zheng Shusen
Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou 310003, China.
Department of Pathology, The First Affiliated Hospital, Zhejiang University School of MedicineHangzhou 310003, China; Department of Pathology and Molecular Medicine, Faculty of Health Science, McMaster UniversityHamilton, Ontario, Canada L8S 4K1.
Int J Clin Exp Pathol. 2015 Nov 1;8(11):14765-71. eCollection 2015.
N-acetyltransferase 10 (NAT10) is a nucleolar protein involved in histone acetylation, telomerase activity regulation, DNA damage response and cytokinesis. The expression of NAT10 was found to be enhanced in several types of tumors, suggesting its correlation with tumor development. However, the specific role of NAT10 in hepatocellular carcinoma (HCC) is still unclear. The aim of this study was to investigate the expression of NAT10 in HCC patients and to assess the relationship of NAT10 expression with clinicopathological characteristics and tumor prognosis. We selected 17 pairs of HCC samples and adjacent non-neoplastic tissue for mRNA expression analysis. We also performed immunohistochemistry in 186 HCC samples to evaluate the NAT10 protein expression. Cox regression and Kaplan-Meier analysis was used to study the diagnostic and prognostic value of NAT10. The results showed that NAT10 expression was mainly localized in the nuclei/nucleoli and was significantly higher in HCC tissues than peritumoral tissues (P < 0.01). High NAT10 expression was positively correlated with histological differentiation (P < 0.01) and TNM classification (P < 0.01). Cox regression univariate and multivariable analysis revealed that expression of NAT10 in HCC was an independent prognostic factor for patient survival time. Our data suggested that NAT10 might be a promising prognostic marker and potential therapeutic target in HCC.
N-乙酰基转移酶10（NAT10）是一种核仁蛋白，参与组蛋白乙酰化、端粒酶活性调节、DNA损伤反应和细胞分裂。研究发现，NAT10在多种肿瘤中表达增强，提示其与肿瘤发生发展相关。然而，NAT10在肝细胞癌（HCC）中的具体作用仍不清楚。本研究旨在探讨NAT10在HCC患者中的表达情况，并评估NAT10表达与临床病理特征及肿瘤预后的关系。我们选取了17对HCC样本及癌旁非肿瘤组织进行mRNA表达分析。我们还对186例HCC样本进行了免疫组织化学检测，以评估NAT10蛋白表达。采用Cox回归和Kaplan-Meier分析研究NAT10的诊断和预后价值。结果显示，NAT10表达主要定位于细胞核/核仁，在HCC组织中的表达显著高于瘤旁组织（P < 0.01）。NAT10高表达与组织学分化（P < 0.01）和TNM分期（P < 0.01）呈正相关。Cox回归单因素和多因素分析显示，HCC中NAT10表达是患者生存时间的独立预后因素。我们的数据表明，NAT10可能是HCC中有前景的预后标志物和潜在治疗靶点。
